Gastrointestinal and hepatobiliary disorders

1 paper1 finding

Humans1

Associations

1

GLP-1 receptor agonists

downin humans1HR 0.77

1 study

GLP-1 receptor agonists lower the risk of gastrointestinal and hepatobiliary disorders in humans (HR 0.77, 95% CI 0.75-0.78).
Humanscompared to DPP-4 inhibitor treatment
A Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Reducing the Incidence of Tuberculosis and Mortality in Patients with Diabetes
Preprints.org10 Sep 2026Preprint

More on GLP-1 receptor agonists

Latest

1 in 12 months

Preprints.org12 Sep

A Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Reducing the Incidence of Tuberculosis and Mortality in Patients with Diabetes

Preprint: cohort study in peopleGLP-1 receptor agonists